Exelixis (NASDAQ:EXEL) announces positive results from an open-label Phase 1b clinical trial, COSMIC-021, evaluating the combination of Cabometyx (cabozantinib) and Roche’s Tecentriq (atezolizumab) in patients with solid tumors.
Data from the metastatic castration-resistant
prostate cancer cohort showed an objective response rate (ORR), the
primary endpoint, of 32%, including two complete responders. The disease
control rate (responders + stable cancer) was 80%. Median duration of
response was 8.3 months, Median follow-up was 12.6 months.
On the safety front, the most common
serious/life-threatening treatment-related adverse events were fatigue
(7%), diarrhea (7%) and hyponatremia (low sodium levels in the blood)
(7%). There was one treatment-related death due to dehydration
(90-year-old patient).
Collaboration partner Ipsen (OTCPK:IPSEY) is participating in the study and is contributing funding. Roche is providing product.
The results will be presented on Thursday at the ASCO GU Cancers Symposium in San Francisco
https://seekingalpha.com/news/3540434-exelixis-cabozantinib-combo-shows-encouraging-action-in-prostate-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.